Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns News Sentiment Score of 0.11

News headlines about Brainstorm Cell Therapeutics (NASDAQ:BCLI) have trended somewhat positive on Sunday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Brainstorm Cell Therapeutics earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an effect on the company’s share price in the next few days.

Brainstorm Cell Therapeutics (BCLI) traded down 0.89% during midday trading on Friday, reaching $4.47. The company had a trading volume of 38,051 shares. Brainstorm Cell Therapeutics has a one year low of $2.06 and a one year high of $5.10. The stock’s 50 day moving average is $4.13 and its 200 day moving average is $3.66. The company’s market capitalization is $83.75 million.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its earnings results on Monday, May 15th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.20. Equities research analysts forecast that Brainstorm Cell Therapeutics will post ($0.79) earnings per share for the current fiscal year.

A number of equities research analysts recently commented on BCLI shares. Maxim Group set a $8.00 price target on Brainstorm Cell Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, June 13th. ValuEngine lowered Brainstorm Cell Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday.

TRADEMARK VIOLATION WARNING: This story was originally published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://transcriptdaily.com/2017/07/16/brainstorm-cell-therapeutics-bcli-earns-daily-media-impact-rating-of-0-11-updated-updated-updated.html.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Insider Buying and Selling by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Receive News & Ratings for Brainstorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply